Biotech News
Related news
AVIRAtea2026-08-05 11:00 EST
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
AVIRAtea2026-08-12 20:05 EST
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
IMNNImunon2026-11-02 13:30 EST
IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026
SIGASIGA Technologies Inc2026-10-29 11:30 EST
SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results
ENTAEnanta Pharmaceuticals2026-08-10 20:01 EST
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
SCYXSCYNEXIS2026-11-05 13:20 EST
SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
IMNNImunon2026-08-04 12:00 EST
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
SIGASIGA Technologies Inc2026-07-30 11:30 EST
SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
VIRIVirios Therapeutics2026-11-05 13:30 EST
Dogwood Therapeutics Announces Third Quarter 2026 Financial Results
ASMBAssembly Biosciences2026-08-13 20:00 EST
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
Atea
Oral Antiviral Therapeutics Atea Pharmaceuticals develops oral antiviral therapies for serious viral diseases. Its pipeline is built around nucleotide and nucleoside analog chemistry and combination treatment strategies. Bemnifosbuvir and Ruzasvir The lead regimen combines the nucleotide polymerase inhibitor bemnifosbuvir with the NS5A...
Recent company news
AVIRAtea2026-11-02 21:05 EST
Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026
AVIRAtea2026-09-08 11:00 EST
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
AVIRAtea2026-08-12 20:05 EST
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
AVIRAtea2026-08-05 11:00 EST
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
AVIRAtea2026-07-28 11:00 EST
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Stock data
- Close
- 4.22 USD
- Market cap
- 341.72M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States